Searched for
DS BRAR
Goldman Sachs set to buy 33% stake in GVK Bio at Rs 7,300-crore valuationThe other contenders included Carlyle Group, Warburg Pincus, General Atlantic and Quadria Capital, as well as Singapore’s Temasek Holdings.17 May, 2021, 08.14 AM IST- Goldman, Temasek, Carlyle vie for 30% stake in GVK BioInvestor will buy out ChrysCapital stake; co-promoters looking to monetise holding08 Jan, 2021, 07.54 AM IST
- Global PE funds eye stake in GVK Bio, co valued at $800 mnIn this proposed transaction, GVK BIO- promoted by the GVK Group and DS Brar, the former CEO and managing director of Ranbaxy Laboratories,...06 Nov, 2020, 12.09 AM IST
- GSK’s former India chief advising KKR on its $4.5-billion horlicks bidAhmed has been advising KKR as an “external consumer industry” consultant since last month.27 Aug, 2018, 07.25 AM IST
- Sun Pharma looks beyond generics at experimental drugsThis sum cited above includes over $200 million that it may spend in Phase III clinical trials and the $80 million that it has committed up...07 Oct, 2014, 10.15 PM IST
- Ranbaxy ex-CEO DS Brar may buy bungalow in LutyensFormer Ranbaxy CEO DS Brar, currently chairman of GVK Bio, is close to buying a bungalow in Delhi’s posh Sunder Nagar, said two persons hav...11 Sep, 2014, 06.15 AM IST
- Almost four years after Daiichi Sankyo's acquisition, Ranbaxy back on track with low-cost version of LipitorRanbaxy has started exporting a low-cost version of cholesterol-lowering blockbuster Lipitor to the US from its new facility in Mohali in P...04 Apr, 2012, 04.12 AM IST
- Mylan sells stake in Concord BiotechWorld’s second-largest generic drug maker Mylan, which held a majority stake in Ahmedabad-based Concord Biotech through its subsidiary Matr...08 Dec, 2009, 12.08 AM IST
- Pharma cos to get less time to correct manufacturing flawsIndia has the highest number of FDA-approved drug plants outside the US, making it one of the largest suppliers to the world’s top pharma m...15 Sep, 2009, 01.43 AM IST
- DS Brar happy, sees pact as trendsetterThe man credited for converting Ranbaxy into an Indian MNC, Mr Brar, today feels the Ranbaxy-Daiichi Sankyo deal is good for all the stake ...12 Jun, 2008, 02.00 AM IST
- GVK Bio eyes 100-cr PE dealGVK Bio, a provider of contract research services for pharmaceutical and biotechnology companies, expects to raise Rs 100 crore in private ...08 Oct, 2007, 04.45 AM IST
- Entrepreneurship bug bites pharma, biotech execsSenior professionals have earned enough expertise to start their own ventures at a time when the market and funding options are favourable.30 Jul, 2007, 12.26 AM IST
- Pillion ride to etrepreneurshipProfessionals in pharma and biotechnology companies are increasingly taking the plunge to set up start-ups - a trend which investors descri...28 Jul, 2007, 02.59 AM IST
- ICICI Bank to play bigger role in M&A financingICICI Bank will play a larger role in financing M&A deals for Indian companies looking abroad.26 Jun, 2007, 04.07 AM IST
- CII to tap scholars to widen India’s billionaire clubAspiring to create a pool of Indian MNCs, the CII Indian MNCs’ Committee is set to bring together eminent scholars from across the globe to...03 Oct, 2006, 12.45 AM IST
- Kumar Mangalam steps down from Tata Steel boardKumar Mangalam Birla, the chairman of the Aditya Birla group, has stepped down from the board of Tata Steel months after relations between ...17 Aug, 2006, 12.57 AM IST
- China top of agenda at CII council meetThe proverbial ghost, China again tops the agenda for India Inc. The national council meeting of CII this week includes a session on lesson...12 Dec, 2002, 06.50 AM IST
Load More
